Novavax, Inc.  

(Public, NASDAQ:NVAX)   Watch this stock  
Find more results for NVAX
9.15
-0.16 (-1.72%)
After Hours: 9.15 0.00 (0.00%)
Feb 27, 4:23PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.51 - 9.25
52 week 3.34 - 9.83
Open 8.65
Vol / Avg. 5.20M/6.69M
Mkt cap 2.23B
P/E     -
Div/yield     -
EPS -0.30
Shares 238.48M
Beta 1.18
Inst. own 64%
Feb 26, 2015
Q4 2014 Novavax Inc Earnings Call
Feb 26, 2015
Q4 2014 Novavax Inc Earnings Release
Jan 14, 2015
Novavax Inc at JPMorgan Healthcare Conference
Dec 3, 2014
Novavax Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -240.16% -248.54%
Operating margin -240.92% -250.70%
EBITD margin - -235.88%
Return on average assets -26.18% -30.81%
Return on average equity -29.12% -36.68%
Employees 213 -
CDP Score - -

Address

20 FIRSTFIELD ROAD
GAITHERSBURG, MD 20878
United States - Map
+1-240-2682000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company�s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional nanostructures, which incorporate immunologically important recombinant proteins. In July 2013, Novavax acquired approximately 97.4% of shares in Isconova AB.

Officers and directors

James F. Young Ph.D. Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Stanley C. Erck President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Barclay A. Phillips Chief Financial Officer, Senior Vice President, Treasurer
Age: 51
Bio & Compensation  - Reuters
Gregory M. Glenn M.D. Senior Vice President - Research & Development
Age: 60
Bio & Compensation  - Reuters
Sven Andreasson Senior Vice President - Corporate Development
Age: 63
Bio & Compensation  - Reuters
Timothy J. Hahn Ph.D. Senior Vice President - Manufacturing and Process Development
Age: 50
Bio & Compensation  - Reuters
Cynthia N. Oliver Ph.D. Senior Vice President - Process Development Operations
Bio & Compensation  - Reuters
John J. Trizzino Senior Vice President - Commercial Operations
Age: 51
Bio & Compensation  - Reuters
Russell P. Wilson J.D. Senior Vice President - Business Development
Age: 54
Bio & Compensation  - Reuters
Louis F. Fries Vice President, Chief Medical Officer
Bio & Compensation  - Reuters